Orphazyme A/S [ORPH] Stock trading around $0.90 per share: What’s Next?


Orphazyme A/S [NASDAQ: ORPH] jumped around 0.25 points on Thursday, while shares priced at $0.90 at the close of the session, up 37.40%. The company report on March 10, 2022 that Commencement of in-court restructuring of Orphazyme A/S.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


Orphazyme A/SCompany announcementNo. 10/2022Inside informationwww.orphazyme.comCompany Registration No. 32266355.

Will institute a reduction of approximately 50% of current work force.

Orphazyme A/S stock is now -62.66% down from its year-to-date (YTD) trading value. ORPH Stock saw the intraday high of $1.00 and lowest of $0.76 per share. The company’s 52-week high price is 77.77, which means current price is +76.44% above from all time high which was touched on 01/03/22.

Compared to the average trading volume of 1.11M shares, ORPH reached a trading volume of 15532682 in the most recent trading day, which is why market watchdogs consider the stock to be active.

What do top market gurus say about Orphazyme A/S [ORPH]?

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ORPH shares is $1.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ORPH stock is a recommendation set at 4.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Guggenheim have made an estimate for Orphazyme A/S shares, keeping their opinion on the stock as Sell, with their previous recommendation back on June 21, 2021. While these analysts kept the previous recommendation, BofA Securities raised their target price from $13 to $5. The new note on the price target was released on March 30, 2021, representing the official price target for Orphazyme A/S stock. Previously, the target price had yet another raise to $27, while Guggenheim analysts kept a Buy rating on ORPH stock.

The Average True Range (ATR) for Orphazyme A/S is set at 0.19, with the Price to Sales ratio for ORPH stock in the period of the last 12 months amounting to 19.88. The Price to Book ratio for the last quarter was 1.29, with the Price to Cash per share for the same quarter was set at 1.17.

How has ORPH stock performed recently?

Orphazyme A/S [ORPH] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -28.57. With this latest performance, ORPH shares dropped by -57.75% in over the last four-week period, additionally sinking by -80.43% over the last 6 months – not to mention a drop of -92.73% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ORPH stock in for the last two-week period is set at 36.10, with the RSI for the last a single of trading hit 39.91, and the three-weeks RSI is set at 34.81 for Orphazyme A/S [ORPH]. The present Moving Average for the last 50 days of trading for this stock 1.7736, while it was recorded at 0.6838 for the last single week of trading, and 4.1159 for the last 200 days.

Orphazyme A/S [ORPH]: Deeper insight into the fundamentals

Return on Total Capital for ORPH is now -148.19, given the latest momentum, and Return on Invested Capital for the company is -164.77. Return on Equity for this stock declined to -188.05, with Return on Assets sitting at -126.24. When it comes to the capital structure of this company, Orphazyme A/S [ORPH] has a Total Debt to Total Equity ratio set at 11.40. Additionally, ORPH Total Debt to Total Capital is recorded at 10.23, with Total Debt to Total Assets ending up at 8.60. Long-Term Debt to Equity for the company is recorded at 5.43, with the Long-Term Debt to Total Capital now at 4.88.

Reflecting on the efficiency of the workforce at the company, Orphazyme A/S [ORPH] managed to generate an average of -$4,491,106 per employee.Orphazyme A/S’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.80 and a Current Ratio set at 1.80.

Insider trade positions for Orphazyme A/S [ORPH]

Positions in Orphazyme A/S stocks held by institutional investors increased at the end of April and at the time of the April reporting period, where 10 institutional holders increased their position in Orphazyme A/S [NASDAQ:ORPH] by around 707,403 shares. Additionally, 13 investors decreased positions by around 409,537 shares, while 2 investors held positions by with 211,844 shares. The mentioned changes placed institutional holdings at 1,328,784 shares, according to the latest SEC report filing. ORPH stock had 3 new institutional investments in for a total of 236,473 shares, while 5 institutional investors sold positions of 156,664 shares during the same period.